Mao M - Search Results

1

Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells.

Mao M, Fang X, Lu Y, Lapushin R, Bast RC Jr, Mills GB. Mao M, et al. Biochem J. 2000 Dec 1;352 Pt 2(Pt 2):475-82. Biochem J. 2000. PMID: 11085941 Free PMC article.

2

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway.

Fang X, Yu S, Eder A, Mao M, Bast RC Jr, Boyd D, Mills GB. Fang X, et al. Among authors: mao m. Oncogene. 1999 Nov 18;18(48):6635-40. doi: 10.1038/sj.onc.1203076. Oncogene. 1999. PMID: 10597268

3

The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells.

Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. Lu Y, et al. Among authors: mao m. Oncogene. 1999 Nov 25;18(50):7034-45. doi: 10.1038/sj.onc.1203183. Oncogene. 1999. PMID: 10597304

4

Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Furui T, et al. Among authors: mao m. Clin Cancer Res. 1999 Dec;5(12):4308-18. Clin Cancer Res. 1999. PMID: 10632375

5

Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase.

Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K, Mills GB. Cuevas BD, et al. Among authors: mao m. J Biol Chem. 2001 Jul 20;276(29):27455-61. doi: 10.1074/jbc.M100556200. Epub 2001 May 3. J Biol Chem. 2001. PMID: 11337495 Free article.

6

Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.

Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Mills GB, et al. Among authors: mao m. Cancer Treat Res. 2002;107:259-83. doi: 10.1007/978-1-4757-3587-1_12. Cancer Treat Res. 2002. PMID: 11775454 Review.

7

Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Fang X, et al. Among authors: mao m. Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64. doi: 10.1016/s1388-1981(02)00179-8. Biochim Biophys Acta. 2002. PMID: 12069836 Review.

8

Specific keynote: molecular therapeutics in ovarian cancer.

Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Among authors: mao m. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.

9

Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC Jr, Mills GB. Pustilnik TB, et al. Among authors: mao m. Clin Cancer Res. 1999 Nov;5(11):3704-10. Clin Cancer Res. 1999. PMID: 10589790

10

Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.

Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB. Fang X, et al. Among authors: mao m. Ann N Y Acad Sci. 2000 Apr;905:188-208. doi: 10.1111/j.1749-6632.2000.tb06550.x. Ann N Y Acad Sci. 2000. PMID: 10818454 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,621 results

Search Page